Can eculizumab be discontinued in aHUS?: Case report and review of the literature - Wikidata - awgldk - TriplyDB

Can eculizumab be discontinued in aHUS?: Case report and review of the literature

Can eculizumab be discontinued in aHUS?: Case report and review of the literature

http://www.wikidata.org/entity/Q33434378

about

Atypical Hemolytic Uremic Syndrome: A Brief Review.Complementopathies.The renaissance of complement therapeutics.No Relapse of Calcineurin Inhibitor-Associated Thrombotic Microangiopathy after Discontinuation of Eculizumab.Atypical hemolytic uremic syndrome and eculizumab therapy in children.

P2860

Q33442794-E3690DC5-99FA-43EE-A720-E0CE612870AA Q39142842-9E85F5C9-5928-436D-9C9A-0F4AA1042CFB Q47336749-9ABBB83B-5FFA-4DC6-B195-152322201300 Q50025315-342438B5-F5C6-432B-80C2-B1E6520B4263 Q54207419-56866692-5FF3-45C6-B9E8-3D094CB31B08

P2860

Can eculizumab be discontinued in aHUS?: Case report and review of the literature

http://www.wikidata.org/entity/Q33434378

description

2016 nî lūn-bûn

@nan

2016 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Can eculizumab be discontinued in aHUS?: Case report and review of the literature

@ast

Can eculizumab be discontinued in aHUS?: Case report and review of the literature

@en

type

label

Can eculizumab be discontinued in aHUS?: Case report and review of the literature

@ast

Can eculizumab be discontinued in aHUS?: Case report and review of the literature

@en

prefLabel

Can eculizumab be discontinued in aHUS?: Case report and review of the literature

@ast

Can eculizumab be discontinued in aHUS?: Case report and review of the literature

@en

P1433

Q33434378-1AC42FEF-021F-4CFC-8498-CFB599D56511

P1476

Q33434378-E6AE4888-41C5-4FB7-B9C0-3DB177837D17

P2093

Q33434378-121B6B93-F420-40AC-B595-66C0A5F31990

Q33434378-5453489A-4019-4E1D-90AA-241D6125D3C5

Q33434378-70333478-D279-4F5E-B91E-F77D10E57C3B

Q33434378-848EDE48-E7A9-4DEC-BA65-665AD0B5670B

Q33434378-992FC15C-0F8F-49BE-91F7-CB5BD28CF9DA

Q33434378-BECBC32E-91DC-4A5C-B900-8F09CAF07DE3

Q33434378-D6367632-9C80-4154-88F0-FED164BD51F4

Q33434378-DD53C302-D94E-4A0E-A0D8-2A907A8FA640

Q33434378-F1E83367-E77D-44D5-B319-AB094D49BC59

Q33434378-F4D0A2DE-F721-4157-91AD-F2F1990B2D2F

P275

Q33434378-881D4684-33C1-4A0C-86CC-6318048FD09B

P2860

Q33434378-06B76FD7-2CA2-44A3-BDC4-476D8DFDF9BA

Q33434378-09E9F59D-2F61-4DF8-B3FE-07945263F949

Q33434378-0BF400C1-4E66-4180-A622-42E71F85003D

Q33434378-0D3B9491-702F-4881-9BB2-A69502DE4774

Q33434378-16B03150-D593-4385-8DD8-BF6212583C57

Q33434378-23091D1E-E644-41BD-81F0-BC3B50CB060E

Q33434378-26FECCB7-EA11-4A3D-BE89-3731901396F7

Q33434378-277D211B-9A9D-407B-A18C-9AA1A287BF39

Q33434378-38E80016-C238-4CB6-B7BD-10EA35D584B0

Q33434378-3BC393A3-3E99-441A-9A1F-6B01CC394F47

P304

Q33434378-65BA12C2-CB1E-4449-B5C4-635C97A76C43

P31

Q33434378-0916A03E-C010-4F52-B383-8150BFE3BE6D

Q33434378-13ae307d-48ee-45f2-8efd-01e7dc44aee9

Q33434378-6E1B3E95-3609-4BA6-8BB7-55BF5D60BB91

P356

Q33434378-5B8DB8AC-CDBB-4290-9937-9E002F138D2A

P407

Q33434378-15B91C11-E5A4-43F0-A7E5-8FAC0938D24C

P433

Q33434378-9EAF5B6A-EF63-4966-9936-628858796DB2

P478

Q33434378-13C3B137-7B9F-43C4-98F6-70981BD3877F

P5008

Q33434378-C021364D-A8A7-44E3-BB1B-A073DD136E4C

P577

Q33434378-5EA0C109-6980-4D7E-843F-89D774FAC4F0

P698

Q33434378-D9407790-CA4B-4421-94F3-4CAB81556CD7

P921

Q33434378-0D2943E6-F48B-4A61-84E7-A5ABEB0164A1

Q33434378-31AE3A82-8726-4CA4-B928-F75475AFE7E5

Q33434378-3453EAF5-8B46-45A8-B4A4-1FD40C65B75D

Q33434378-98F90D95-EA9B-452C-939F-FFC22A49BDFE

P932

Q33434378-88636300-1B6C-4866-A3C9-FF7656AD5A71

P356

MD.0000000000004330

P1433

P1476

Can eculizumab be discontinued in aHUS?: Case report and review of the literature

@en

P2093

Abdulkadir Unsal

http://www.w3.org/2001/XMLSchema#string

Cuneyt Akgol

http://www.w3.org/2001/XMLSchema#string

Ekrem Kara

http://www.w3.org/2001/XMLSchema#string

Elbis Ahbap

http://www.w3.org/2001/XMLSchema#string

Feyza Bayraktar Caglayan

http://www.w3.org/2001/XMLSchema#string

Mohamed R Daha

http://www.w3.org/2001/XMLSchema#string

Mustafa Sevinc

http://www.w3.org/2001/XMLSchema#string

Tamer Sakaci

http://www.w3.org/2001/XMLSchema#string

Taner Basturk

http://www.w3.org/2001/XMLSchema#string

Tuncay Sahutoglu

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome

Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype

Atypical hemolytic-uremic syndrome.

Pulse cyclophosphamide therapy and clinical remission in atypical hemolytic uremic syndrome with anti-complement factor H autoantibodies.

Eculizumab therapy in a child with hemolytic uremic syndrome and CFI mutation.

Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome.

Neurologic involvement in atypical hemolytic uremic syndrome and successful treatment with eculizumab.

Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.

Long-term remission of atypical HUS with anti-factor H antibodies after cyclophosphamide pulses.

Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children.

P304

e4330

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/MD.0000000000004330

http://www.w3.org/2001/XMLSchema#string

P407

P433

31

http://www.w3.org/2001/XMLSchema#string

P478

95

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2016-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27495036

http://www.w3.org/2001/XMLSchema#string

P921

Atypical hemolytic uremic syndrome

monoclonal antibody

P932

4979790

http://www.w3.org/2001/XMLSchema#string